Rezolute Announces $25 Million Private Placement -- Potential Total Investment of $45 Million
07. Januar 2019 08:39 ET
|
Rezolute, Inc.
REDWOOD CITY, Calif., Jan. 07, 2019 (GLOBE NEWSWIRE) -- Rezolute, Inc. (“Rezolute” or “Company”) (OTCQB:RZLT), a clinical stage biopharmaceutical company specializing in the development of...
Rezolute Announces Appointment of Keith Vendola as Chief Financial Officer
16. Mai 2018 08:00 ET
|
Rezolute, Inc.
LOUISVILLE, Colo., May 16, 2018 (GLOBE NEWSWIRE) -- Rezolute, Inc. (“Rezolute” or the “Company”) (OTCQB:RZLT), a clinical stage biopharmaceutical company specializing in the development of...
Rezolute Announces Appointment of Congenital Hyperinsulinism Therapeutic Area Expert, Dr. Christine Ferrara, as Director of Clinical Development
09. April 2018 08:00 ET
|
Rezolute, Inc.
LOUISVILLE, Colo., April 09, 2018 (GLOBE NEWSWIRE) -- Rezolute, Inc. (“Rezolute” or the “Company”) (OTCQB:RZLT), a clinical stage biopharmaceutical company specializing in the development of...
Rezolute Announces Appointment of Hoyoung Huh, M.D., Ph.D. as Vice Chairman of its Board of Directors
04. April 2018 08:00 ET
|
Rezolute, Inc.
LOUISVILLE, Colo., April 04, 2018 (GLOBE NEWSWIRE) -- Rezolute, Inc. (“Rezolute” or the “Company”) (OTCQB:RZLT), a clinical stage biopharmaceutical company specializing in the development of...
Rezolute, Inc. Announces Close of Convertible Note Financing
03. April 2018 13:26 ET
|
Rezolute, Inc.
LOUISVILLE, Colo., April 03, 2018 (GLOBE NEWSWIRE) -- Rezolute, Inc. (“Rezolute” or the “Company”) (OTCQB:RZLT), a clinical stage biopharmaceutical company specializing in the development of...
UPDATE - Rezolute, Inc. Enters into Common Stock Purchase Agreement for Up to $10 Million with Lincoln Park Capital Fund, LLC
26. Dezember 2017 11:41 ET
|
Rezolute, Inc.
LOUISVILLE, Colo., Dec. 26, 2017 (GLOBE NEWSWIRE) -- Rezolute, Inc. (“Rezolute” or the “Company”) (OTCQB:RZLT), a clinical stage biopharmaceutical company specializing in the development of...
Rezolute, Inc. Enters into Common Stock Purchase Agreement for Up to $10 Million with Lincoln Park Capital Fund, LLC
26. Dezember 2017 08:00 ET
|
Rezolute, Inc.
LOUISVILLE, Colo., Dec. 26, 2017 (GLOBE NEWSWIRE) -- Rezolute, Inc. (“Rezolute” or the “Company”) (OTCQB:RZLT), a clinical stage biopharmaceutical company specializing in the development of...
AntriaBio Announces Exclusive License Agreement for a Phase 2 Orphan Disease Therapy with XOMA Corporation and Name Change to Rezolute, Inc.
07. Dezember 2017 08:30 ET
|
Rezolute, Inc.
LOUISVILLE, Colo., Dec. 07, 2017 (GLOBE NEWSWIRE) -- Rezolute, Inc. (“Rezolute” or the “Company”) (OTCQB:ANTB), a clinical stage biopharmaceutical company specializing in the development of...
AntriaBio Announces Selection of Lead Oral Plasma Kallikrein Inhibitor Candidates for the Treatment of Diabetic Retinopathy, Diabetic Macular Edema and Hereditary Angioedema
17. Oktober 2017 08:00 ET
|
AntriaBio, Inc.
LOUISVILLE, Colo., Oct. 17, 2017 (GLOBE NEWSWIRE) -- AntriaBio, Inc. (“AntriaBio” or the “Company”) (OTCQB:ANTB), a biopharmaceutical company focused on developing therapies to address significant...
AntriaBio Appoints Nektar Therapeutics CFO to its Board of Directors
09. Oktober 2017 08:00 ET
|
AntriaBio, Inc.
LOUISVILLE, Colo., Oct. 09, 2017 (GLOBE NEWSWIRE) -- AntriaBio, Inc. (“AntriaBio” or the “Company”) (OTCQB:ANTB), a biopharmaceutical company specializing in the development of innovative drug...